Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

ORIC
Oric Pharmaceuticals, Inc. Common Stock
stock NASDAQ

At Close
Aug 4, 2026 3:59:59 PM EDT
13.51USD+27.573%(+2.92)5,042,355
11.57Bid   15.50Ask   3.93Spread
Pre-market
Aug 4, 2026 8:57:30 AM EDT
10.90USD+2.927%(+0.31)3,756
After-hours
Aug 4, 2026 4:34:30 PM EDT
13.30USD-1.554%(-0.21)474,948
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 25, 2022
08:39AM EST  ORIC Pharma Announces CTA Clearance For ORIC-114 In Advanced Solid Tumors With EGFR Or HER2 Exon 20 Alterations   RTTNews
08:37AM EST  ORIC Pharmaceuticals Announces Korean Regulatory Clearance Of Clinical Trial Application For ORIC-114 In Advanced Solid Tumors With EGFR Or HER2 Exon 20 Alterations Or HER2 Amplifications   Benzinga
08:30AM EST  ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical   GlobeNewswire Inc
Jan 10, 2022
08:00AM EST  ORIC-101 program on track for updates from both ongoing clinical trials in first half of 2022   GlobeNewswire Inc
Jan 4, 2022
04:30PM EST  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 3:00 p.m. ET.   GlobeNewswire Inc
Dec 13, 2021
04:16PM EST  ORIC Pharma Highlights Presentation Of Data Supporting Therapeutic Potential Of ORIC-533 In Multiple Myeloma At American Society Of Hematology Meeting   Benzinga
04:15PM EST  CD73 inhibition overcomes immunosuppression and demonstrates activity in assays derived from relapsed or refractory multiple myeloma patients, offering the potential for single agent activity in the clinic   GlobeNewswire Inc
Dec 9, 2021
04:30PM EST  Call to discuss poster presentation on ORIC CD73 inhibitor in human ex vivo multiple myeloma systems presented at the American Society of Hematology (ASH) Annual Meeting   GlobeNewswire Inc
Nov 29, 2021
04:00PM EST  Bright Peak Therapeutics Appoints Jacob Chacko, M.D., as Chair of   GlobeNewswire Inc
Nov 11, 2021
04:15PM EST  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences:   GlobeNewswire Inc
Nov 10, 2021
09:09AM EST  HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $31   Benzinga
Nov 9, 2021
11:09AM EST  ORIC Pharmaceuticals Q3 EPS $(0.47) Up From $(0.84) YoY   Benzinga
Nov 8, 2021
04:05PM EST  Initial clinical data from Phase 1b trial of ORIC-101 in combination with enzalutamide and preclinical data on ORIC-114 presented at AACR-NCI-EORTC   GlobeNewswire Inc
Nov 4, 2021
09:28AM EDT  ORIC Pharmaceuticals To Present Update On CD73 Inhibitor Program In Multiple Myeloma At American Society Of Hematology (ASH) Annual Meeting   Benzinga
Oct 8, 2021
10:43AM EDT  UPDATE: Citi On ORIC Pharmaceuticals Price Target Cut: Firm Sees 'Smaller Addressable mCRPC Population & Lower Peak Share' Than Previous Estimates Following ORIC-101 Data Release; Highlights Rich Pipeline ORIC-114, ORIC-553, & ORIC-944 For Favorable R/R   Benzinga
10:42AM EDT  Citi Maintains Buy Rating On ORIC Pharmaceuticals And Lowers Price Target From $33 To $22   Benzinga
06:23AM EDT  HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $30   Benzinga
Oct 7, 2021
03:12PM EDT  Mid-Afternoon Market Update: Crude Oil Rises 1%; New Fortress Energy Shares Spike Higher   Benzinga
12:28PM EDT  Mid-Day Market Update: Dow Jumps Over 500 Points; Osmotica Pharmaceuticals Shares Slide   Benzinga
10:44AM EDT  Mid-Morning Market Update: Markets Open Higher; Conagra Brands Profit Beats Views   Benzinga
08:56AM EDT  ORIC Pharmaceuticals Presents Initial Clinical Data From Phase 1b Trial Of ORIC-101 In Combination With Enzalutamide And Preclinical Data On ORIC-114 at AACR-NCI-EORTC   Benzinga
08:55AM EDT  ORIC-101 and enzalutamide combination regimen at the recommended Phase 2 dose was well tolerated; adverse events generally consistent with single agent enzalutamide   GlobeNewswire Inc
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 3, 2021
02:21PM EDT  The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs and More   Benzinga
Sep 30, 2021
04:32PM EDT  ORIC Pharmaceuticals Announces Multiple Data Presentations At AACR-NCI-EORTC Virtual International Conference On Molecular Targets And Cancer Therapeutics   Benzinga
04:30PM EDT  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced three poster presentations at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics to be held October 7-10, 2021.   GlobeNewswire Inc
Sep 21, 2021
06:40AM EDT  ORIC Expects To Enroll First Patient In ORIC-533 Trial Will Be Enrolled During Q4   Benzinga
06:30AM EDT  ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly   GlobeNewswire Inc
Sep 1, 2021
08:00AM EDT  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in September:   GlobeNewswire Inc
Aug 16, 2021
04:15PM EDT  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of 25-year industry veteran Steven L. Hoerter to its Board of Directors.   GlobeNewswire Inc
Aug 11, 2021
06:32AM EDT  HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $53   Benzinga
Aug 10, 2021
05:02PM EDT  ORIC Pharmaceuticals Q2 EPS $(0.57) Down From $(0.51) YoY   Benzinga
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 6, 2021
10:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2021   Benzinga
09:32AM EDT  Citigroup Upgrades ORIC Pharmaceuticals to Buy, Announces $34 Price Target   Benzinga
Jun 30, 2021
07:29AM EDT  The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs   Benzinga
Jun 29, 2021
08:17AM EDT  The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout   Benzinga
Jun 28, 2021
08:22AM EDT  ORIC Pharma Announces FDA Clearance Of IND Application For ORIC-533   RTTNews
08:06AM EDT  ORIC Pharmaceuticals Announces FDA Clearance Of IND Application For ORIC-533, A Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor   Benzinga
08:00AM EDT  ORIC expects to initiate single agent clinical trial in an undisclosed tumor type in 2H21   GlobeNewswire Inc
Jun 24, 2021
08:12AM EDT  The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO   Benzinga
Jun 23, 2021
07:35AM EDT  The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway   Benzinga
Jun 17, 2021
08:33AM EDT  The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme   Benzinga
Jun 3, 2021
08:23AM EDT  The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout   Benzinga
08:22AM EDT  Oric Pharma's ORIC-101 Shows Tumor Regression, Prolonged Stable Disease in Multiple Heavily Pretreated Tumors   Benzinga
Jun 2, 2021
04:55PM EDT  ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented At ASCO From Phase 1b Trial Of ORIC-101 In Combination With Nab-Paclitaxel   Benzinga
04:55PM EDT  Initial safety data showed combination regimen at the recommended Phase 2 dose was well tolerated; treatment-related adverse events primarily Grade 1 or 2, with no treatment-related discontinuations   GlobeNewswire Inc
May 26, 2021
04:30PM EDT  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021, at 1:30 p.m. ET.   GlobeNewswire Inc
May 25, 2021
08:00AM EDT  ORIC Pharmaceuticals to Host Conference Call with KOL to Review   GlobeNewswire Inc
May 6, 2021
04:51PM EDT  ORIC Pharmaceuticals Q1 EPS $(0.45) Up From $(4.46) YoY   Benzinga
Apr 28, 2021
04:41PM EDT  ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel at the 2021 ASCO Annual Meeting   Benzinga
04:05PM EDT  ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b   GlobeNewswire Inc
Apr 12, 2021
06:31AM EDT  ORIC Pharmaceuticals Presents Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting   Benzinga
06:30AM EDT  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of resistance in cancer, presented four preclinical poster presentations at the 2021 American Association for Cancer Research (AACR) virtual annual meeting.   GlobeNewswire Inc
Mar 25, 2021
07:57AM EDT  10 Biggest Price Target Changes For Thursday   Benzinga
06:39AM EDT  HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $54   Benzinga
Mar 23, 2021
04:10PM EDT  ORIC Pharmaceuticals Q4 EPS $(0.84) Up From $(4.27) YoY   Benzinga
04:05PM EDT  ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020   GlobeNewswire Inc
Mar 10, 2021
04:34PM EST  ORIC Pharma Will Present Posters On 4 Programs At American Association For Cancer Research Apr. 10-15   Benzinga
04:30PM EST  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of resistance in cancer, today announced four preclinical poster presentations at the 2021 American Association for Cancer Research (AACR) virtual annual meeting on April 10-15, 2021.   GlobeNewswire Inc
Mar 2, 2021
06:30AM EST  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will present a company overview at the following investor conferences in March:   GlobeNewswire Inc
Feb 3, 2021
04:30PM EST  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in February:   GlobeNewswire Inc
Jan 25, 2021
10:07AM EST  Citigroup Downgrades ORIC Pharmaceuticals to Neutral   Benzinga
Jan 11, 2021
06:39AM EST  ORIC Pharmaceuticals Announces Lead Program ORIC-101 Continues Patient Enrollment Investigating Two Therapeutic Mechanisms Of Action And On Track For Two Initial Data Readouts In 2021   Benzinga
06:30AM EST  Lead program ORIC-101 continues patient enrollment investigating two therapeutic mechanisms of action and on track for two initial data readouts in 2021   GlobeNewswire Inc
Jan 4, 2021
06:30AM EST  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 12:40 p.m. PT.   GlobeNewswire Inc
Dec 21, 2020
06:31AM EST  ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101   Benzinga
06:30AM EST  Initiated Part II expansion of the Phase 1b study of ORIC-101 in combination with Abraxane (nab-paclitaxel) using recommended Phase 2 dose selected from Part I of the study   GlobeNewswire Inc
Nov 17, 2020
04:15PM EST  ORIC Pharmaceuticals Announces Closing of Public Offering and Full   GlobeNewswire Inc
Nov 13, 2020
06:34AM EST  ORIC Pharma Prices 5.04M Share Offering At $23/Share   Benzinga
06:33AM EST  AECOM Shares ORIC Pharma Prices 5.04M Share Offering At $23/Share   Benzinga
06:32AM EST  ORIC Pharmaceuticals Announces Pricing of Upsized Public Offering   GlobeNewswire Inc
Nov 11, 2020
07:38AM EST  The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap   Benzinga
Nov 10, 2020
04:33PM EST  ORIC Pharmaceuticals Announces A 4M Share Common Stock Offering, No Price Was Disclosed   Benzinga
04:05PM EST  ORIC Pharmaceuticals Announces Proposed Public Offering of Common   GlobeNewswire Inc
Nov 9, 2020
06:30AM EST  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will participate in the following investor conferences in November:   GlobeNewswire Inc
Nov 5, 2020
04:44PM EST  ORIC Pharmaceuticals Q3 EPS $(0.84) Up From $(3.36) YoY   Benzinga
Oct 20, 2020
08:17AM EDT  The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger   Benzinga
Oct 19, 2020
04:05PM EDT  ORIC Pharmaceuticals Expands Precision Oncology Pipeline With Exclusive License To Brain Penetrant EGFR/HER2 20 Inhibitor Program   Benzinga
04:03PM EDT  ORIC Pharmaceuticals Enters Exclusive License Agreement With Voronoi For Exclusive License For ORIC-114   Benzinga
04:02PM EDT  ORIC-114 is a potential best-in-class inhibitor designed for brain penetrance and selectivityfor exon20 insertion mutations of EGFR and HER2   GlobeNewswire Inc
Oct 9, 2020
06:31AM EDT  ORIC Pharma Highlights Presentation Of Preclinical Data On Glucocorticoid Receptor Antagonist Overcoming Resistance To Androgen Receptor Degrader At Upcoming Symposium Oct. 24-25   Benzinga
06:30AM EDT  ORIC Pharmaceuticals Announces Presentation of Preclinical Data on   GlobeNewswire Inc
Sep 2, 2020
04:30PM EDT  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will participate in the following investor conferences in September:   GlobeNewswire Inc
Aug 13, 2020
06:14AM EDT  Baird Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $45   Benzinga
Aug 5, 2020
04:59PM EDT  ORIC Pharmaceuticals Q2 EPS $(0.51) Misses $(0.40) Estimate   Benzinga
04:21AM EDT  Earnings Scheduled For August 5, 2020   Benzinga
Aug 3, 2020
10:15PM EDT  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will host a conference call and webcast to discuss its second quarter 2020 financial results and other business highlights on Wednesday, August 5, 2020, at 4:30 p.m. ET.   GlobeNewswire Inc
09:32AM EDT  Benzinga's Top Upgrades, Downgrades For August 3, 2020   Benzinga
06:19AM EDT  HC Wainwright & Co. Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $52   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC